keyword
MENU ▼
Read by QxMD icon Read
search

Exenatide without diabetes

keyword
https://www.readbyqxmd.com/read/27899001/drug-interventions-for-the-treatment-of-obesity-in-children-and-adolescents
#1
REVIEW
Emma Mead, Greg Atkinson, Bernd Richter, Maria-Inti Metzendorf, Louise Baur, Nicholas Finer, Eva Corpeleijn, Claire O'Malley, Louisa J Ells
BACKGROUND: Child and adolescent obesity has increased globally, and can be associated with significant short- and long-term health consequences. OBJECTIVES: To assess the efficacy of drug interventions for the treatment of obesity in children and adolescents. SEARCH METHODS: We searched CENTRAL, MEDLINE, Embase, PubMed (subsets not available on Ovid), LILACS as well as the trial registers ICTRP (WHO) and ClinicalTrials.gov. Searches were undertaken from inception to March 2016...
November 29, 2016: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/27898183/effect-of-exenatide-on-postprandial-glucose-fluxes-lipolysis-and-%C3%A3-cell-function-in-nondiabetic-morbidly-obese-patients
#2
Stefania Camastra, Brenno Astiarraga, Andrea Tura, Silvia Frascerra, Demetrio Ciociaro, Andrea Mari, Amalia Gastaldelli, Ele Ferrannini
AIMS: To investigate the effect of exenatide on glucose disposal, insulin secretion, ß-cell function, lipolysis, and hormone concentrations in non-diabetic, morbidly obese subjects under physiological conditions. MATERIALS AND METHODS: Patients were assigned to exenatide 10 µg twice daily (EXE, n = 15) or control (CT, n = 15) for 3 months. Patients received a meal test/tracer study (MTT) to measure endogenous glucose production (EGP), rate of oral glucose appearance (RaO), insulin secretion rate (ISR), ß-cell function, hepatic (HIR) and adipose tissue insulin resistance (AT-IR) and insulin sensitivity (IS)...
November 29, 2016: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/27669277/the-use-of-exenatide-in-managing-markers-of-cardiovascular-risk-in-patients-with-type-2-diabetes-a-systematic-review
#3
REVIEW
Omorogieva Ojo
OBJECTIVE: This review examines the use of exenatide twice daily in managing changes in markers of cardiovascular risk in patients with type 2 diabetes. BACKGROUND: Type 2 diabetes is a progressive metabolic disorder, which results from defects in insulin secretion and/or insulin action leading to chronic hyperglycaemia and associated cardiovascular complications. Despite the use of diet, exercise, oral antihyperglycaemic agents and insulin, the progressive nature of the condition means that the levels of the preventive and treatment measures would have to be increased and/or new therapies have to be developed in order to address the long term impact of type 2 diabetes...
2016: International Journal of Environmental Research and Public Health
https://www.readbyqxmd.com/read/27550386/dapagliflozin-qd-and-exenatide-qw-dual-therapy-a-24-week-randomized-placebo-controlled-phase-2-study-examining-effects-on-bodyweight-and-prediabetes-in-obese-nondiabetic-adults
#4
Per Lundkvist, C David Sjöström, Sam Amini, Maria J Pereira, Eva Johnsson, Jan W Eriksson
AIMS: Dapagliflozin as well as exenatide reduce bodyweight in patients with type 2 diabetes. We explored the effects of dual therapy with these agents on bodyweight, body composition, glycemic parameters, and systolic blood pressure (SBP) in obese nondiabetic adults. MATERIALS AND METHODS: This single-center, double-blind trial randomized 50 obese nondiabetic adults (aged 18-70 years; body mass index 30-45 kg/m(2) ) to oral dapagliflozin 10 mg once daily plus subcutaneous long-acting exenatide 2 mg once weekly or placebo...
August 23, 2016: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/27531946/glucagon-like-peptide-1-glp-1-receptor-agonists-in-cardiac-disorders
#5
Jamie Wroge, Nancy Toedter Williams
OBJECTIVE: To evaluate the literature about the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in the treatment of cardiac disorders, specifically myocardial infarction (MI) and heart failure (HF). DATA SOURCES: Searches were conducted in MEDLINE (1946-May 2016) and Excerpta Medica (1980-May 2016) using EMBASE with the search terms glucagon-like peptide 1, exenatide, albiglutide, liraglutide, dulaglutide, myocardial infarction, heart failure, and cardiovascular The references of relevant articles were reviewed to identify additional citations...
August 16, 2016: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/27525540/efficacy-and-tolerability-of-exenatide-once-weekly-over-6-years-in-patients-with-type-2-diabetes-an-uncontrolled-open-label-extension-of-the-duration-1-study
#6
Robert R Henry, Eric J Klein, Jenny Han, Nayyar Iqbal
BACKGROUND: Long-term treatment is necessary to slow the progression of type 2 diabetes (T2D). Here, we examined the safety and efficacy of 6 years of treatment with exenatide once weekly (QW) among patients with T2D in the DURATION-1 trial. METHODS: The study enrolled patients aged ≥16 years with T2D treated primarily with metformin and sulfonylureas. Following 30 weeks of randomized treatment with exenatide QW 2 mg or exenatide twice daily 10 μg, patients entered an uncontrolled, open-label, open-ended study phase in which all patients received exenatide QW 2 mg...
November 2016: Diabetes Technology & Therapeutics
https://www.readbyqxmd.com/read/27485823/adjunctive-role-of-glucagon-like-peptide-1-receptor-agonists-in-the-management-of-type-1-diabetes-mellitus
#7
REVIEW
Kira B Harris, Cassie L Boland
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are commonly used in combination with insulin to manage type 2 diabetes mellitus, and four agents are currently approved for this indication: exenatide, liraglutide, dulaglutide, and albiglutide. The distinctive properties of GLP-1 RAs-potential hemoglobin A1c (A1C) reduction, weight loss, potential to reduce insulin doses, and lower hypoglycemia risk-have made these agents potential treatment options for patients with type 1 diabetes mellitus (T1DM) as well...
September 2016: Pharmacotherapy
https://www.readbyqxmd.com/read/27398720/exenatide-treatment-alone-improves-%C3%AE-cell-function-in-a-canine-model-of-pre-diabetes
#8
Viorica Ionut, Orison O Woolcott, Hasmik J Mkrtchyan, Darko Stefanovski, Morvarid Kabir, Malini S Iyer, Huiwen Liu, Ana V B Castro, Qiang Wu, Josiane L Broussard, Cathryn M Kolka, Isaac Asare-Bediako, Richard N Bergman
BACKGROUND: Exenatide's effects on glucose metabolism have been studied extensively in diabetes but not in pre-diabetes. OBJECTIVE: We examined the chronic effects of exenatide alone on glucose metabolism in pre-diabetic canines. DESIGN AND METHODS: After 10 weeks of high-fat diet (HFD), adult dogs received one injection of streptozotocin (STZ, 18.5 mg/kg). After induction of pre-diabetes, while maintained on HFD, animals were randomized to receive either exenatide (n = 7) or placebo (n = 7) for 12 weeks...
2016: PloS One
https://www.readbyqxmd.com/read/27343423/exenatide-in-obese-or-overweight-patients-without-diabetes-a-systematic-review-and-meta-analyses-of-randomized-controlled-trials
#9
Na Su, Yun Li, Ting Xu, Ling Li, Joey Sum-Wing Kwong, Heyue Du, Kaiun Ren, Qianrui Li, Jianshu Li, Xin Sun, Sheyu Li, Haoming Tian
BACKGROUND/OBJECTIVES: Exenatide, a glucagon-like peptide-1 (GLP-1) receptor agonist, is increasingly used in obese or overweight patients with diabetes. However, its safety profile and effects on weight loss in non-diabetic obese or overweight population remain unclear. We aimed to evaluate efficacy and safety of exenatide in obese or overweight participants without diabetes. METHODS: We searched up to January 2016 in MEDLINE (Ovid SP), EMBASE (Ovid SP), Cochrane Central Register of Controlled Trials (CENTRAL), some Chinese databases and ClinicalTrials...
September 15, 2016: International Journal of Cardiology
https://www.readbyqxmd.com/read/27071367/effects-of-exenatide-on-weight-and-appetite-in-overweight-adolescents-and-young-adults-with-prader-willi-syndrome
#10
P Salehi, I Hsu, C G Azen, S D Mittelman, M E Geffner, D Jeandron
BACKGROUND: Prader-Willi syndrome (PWS) is associated with hyperphagia and hyperghrelinemia with major morbidity because of obesity without effective medical treatment targeting hyperphagia. Exenatide (Byetta [synthetic Exendin-4]; AstraZeneca, Wilmington DE) is a GLP-1 receptor agonist which reduces appetite and weight and may be an effective treatment in PWS. OBJECTIVE: The objective of this study is to determine the effect of a 6-month trial of exenatide on appetite, weight and gut hormones in youth with PWS...
April 13, 2016: Pediatric Obesity
https://www.readbyqxmd.com/read/27027802/relationship-of-body-mass-index-with-efficacy-of-exenatide-twice-daily-added-to-insulin-glargine-in-patients-with-type-2-diabetes
#11
B H R Wolffenbuttel, L Van Gaal, S Durán-Garcia, J Han
This post hoc analysis assessed the evidence behind common reimbursement practices by evaluating the relationship of body mass index (BMI) ranges (<30, 30-35 and >35 kg/m(2) ) with treatment effects of exenatide twice daily among patients with type 2 diabetes. Patients received exenatide twice daily added to insulin glargine in two 30-week studies (exenatide twice daily vs insulin lispro, n = 627; exenatide twice daily vs placebo, n = 259). No association of baseline BMI with changes in efficacy variables was observed...
August 2016: Diabetes, Obesity & Metabolism
https://www.readbyqxmd.com/read/26998491/exenatide-treatment-causes-suppression-of-serum-ghrelin-levels-following-mixed-meal-test-in-obese-diabetic-women
#12
Figen Topyildiz, Sinem Kiyici, Zulfiye Gul, Deniz Sigirli, Metin Guclu, Gurcan Kisakol, Sinan Cavun
Aim. To investigate the effect of exenatide treatment on serum ghrelin levels in obese female patients with type 2 diabetes mellitus. Methods. Fourteen female patients with type 2 diabetes mellitus being treated with metformin and exenatide were enrolled. A mixed meal test was applied to the patients while continuing with their daily medications. Blood samples were taken before and at 60, 120, and 180 minutes following mixed meal test to measure serum total ghrelin, glucose, and insulin levels. The following week, exenatide treatment of the patients was paused for 24 hours and the same experimental procedures were repeated...
2016: Journal of Diabetes Research
https://www.readbyqxmd.com/read/26864536/delivery-of-exenatide-and-insulin-using-mucoadhesive-intestinal-devices
#13
Vivek Gupta, Byeong-Hee Hwang, Nishit Doshi, Amrita Banerjee, Aaron C Anselmo, Samir Mitragotri
A major disadvantage associated with current diabetes therapy is dependence on injectables for long-term disease management. In addition to insulin, incretin hormone replacement therapies including exenatide have added a new class of drugs for Type-2 diabetes. Although efficacious, patient compliance with current diabetic therapy is poor due to requirement of injections, inability to cross the intestinal epithelium and instability in the gastrointestinal tract. Here, we report the efficacy of a mucoadhesive device in providing therapeutic concentrations of insulin and exenatide via oral administration...
June 2016: Annals of Biomedical Engineering
https://www.readbyqxmd.com/read/26803355/circulating-adiponectin-levels-in-type-2-diabetes-mellitus-patients-with-or-without-non-alcoholic-fatty-liver-disease-results-of-a-small-open-label-randomized-controlled-intervention-trial-in-a-subgroup-receiving-short-term-exenatide
#14
Savvoula Savvidou, Kyparissia Karatzidou, Kalliopi Tsakiri, Asterios Gagalis, Prodromos Hytiroglou, John Goulis
AIM: Diabetes mellitus type 2 (DMT2) and non-alcoholic fatty liver disease (NAFLD) are both characterized by decreased circulating adiponectin. Recently, glucagon-like peptide-1 receptor agonists have been shown to induce adiponectin's expression. However, their interaction on clinical grounds needs to be further elucidated. METHODS: DMT2 patients with abnormal aminotransferases were screened for NAFLD and subjected to liver biopsy (group A, n=17). A subgroup of patients (n=110), after assessed for eligibility criteria, was blindly randomized to receive either 6-month exenatide supplementation on glargine insulin (group B) or intense, self-regulated, insulin therapy alone (group C)...
March 2016: Diabetes Research and Clinical Practice
https://www.readbyqxmd.com/read/26761217/dulaglutide-ly-2189265-for-the-treatment-of-type-2-diabetes
#15
André J Scheen
Dulaglutide is a new once-weekly glucagon-like peptide-1 receptor agonist for the management of hyperglycemia in adult patients with type 2 diabetes. It stimulates dose-dependent insulin secretion and reduces glucagon secretion, both in a glucose-dependent manner. Efficacy on blood glucose control and safety were demonstrated in the large AWARD program in type 2 diabetic patients treated with diet, metformin, dual oral therapy or insulin lispro with or without metformin, confirming findings of pilot studies in Caucasian patients and data in Japanese patients...
2016: Expert Review of Clinical Pharmacology
https://www.readbyqxmd.com/read/26676329/effects-of-short-term-exenatide-treatment-on-regional-fat-distribution-glycated-hemoglobin-levels-and-aortic-pulse-wave-velocity-of-obese-type-2-diabetes-mellitus-patients
#16
Ju Young Hong, Keun Young Park, Byung Joon Kim, Won Min Hwang, Dong Ho Kim, Dong Mee Lim
BACKGROUND: Most type 2 diabetes mellitus patients are obese and have obesity related vascular complications. Exenatide treatment is well known for both decreasing glycated hemoglobin levels and reduction in body weight. So, this study aimed to determine the effects of exenatide on body composition, glycated hemoglobin levels, and vascular stiffness in obese type 2 diabetes mellitus patients. METHODS: For 1 month, 32 obese type 2 diabetes mellitus patients were administered 5 μg of exenatide twice daily...
March 2016: Endocrinology and Metabolism
https://www.readbyqxmd.com/read/26384381/topical-administration-of-glp-1-receptor-agonists-prevents-retinal-neurodegeneration-in-experimental-diabetes
#17
Cristina Hernández, Patricia Bogdanov, Lidia Corraliza, Marta García-Ramírez, Cristina Solà-Adell, José A Arranz, Ana I Arroba, Angela M Valverde, Rafael Simó
Retinal neurodegeneration is an early event in the pathogenesis of diabetic retinopathy (DR). Since glucagon-like peptide 1 (GLP-1) exerts neuroprotective effects in the central nervous system and the retina is ontogenically a brain-derived tissue, the aims of the current study were as follows: 1) to examine the expression and content of GLP-1 receptor (GLP-1R) in human and db/db mice retinas; 2) to determine the retinal neuroprotective effects of systemic and topical administration (eye drops) of GLP-1R agonists in db/db mice; and 3) to examine the underlying neuroprotective mechanisms...
January 2016: Diabetes
https://www.readbyqxmd.com/read/26205746/exenatide-and-sitagliptin-decrease-interleukin-1%C3%AE-matrix-metalloproteinase-9-and-nitric-oxide-synthase-2-gene-expression-but-does-not-reduce-alveolar-bone-loss-in-rats-with-periodontitis
#18
Renata M Moraes, Gabriela M G Lima, Felipe E Oliveira, Ana Carolina V Brito, Rodrigo C Pereira, Luciane D Oliveira, Patrícia P Barros, Gilson C N Franco, Ana Lia Anbinder
BACKGROUND: New drugs for the treatment of diabetes, glucagon-like peptide-1 (GLP-1) receptor agonists and inhibitors of dipeptidyl peptidase-4 (DPP-4) have shown pleiotropic effects on bone metabolism and anti-inflammatory properties. The aim of this study is to evaluate the effects of exenatide (GLP-1 agonist) and sitagliptin (DPP-4 inhibitor) during periodontitis induction by ligature insertion in rats. METHODS: Forty rats were divided into four groups: 1) animals with induced periodontitis that received exenatide (EG); 2) animals with induced periodontitis that received sitagliptin (SG); 3) animals with induced periodontitis and without drug treatment (LG); and 4) animals without induced periodontitis and without drug treatment (controls)...
November 2015: Journal of Periodontology
https://www.readbyqxmd.com/read/26034806/glucose-lowering-treatment-of-type-2-diabetes-part-ii-glucose-lowering-drugs-after-metformin-a-choice-based-largely-on-adverse-effects
#19
REVIEW
(no author information available yet)
Metformin alone is the glucose-lowering drug of first choice for patients with type 2 diabetes. None of the other glucose-lowering drugs available in 2014 have any proven efficacy in preventing diabetes complications. How important are adverse effects in the choice of glucose-lowering alternatives to metformin for patients with type 2 diabetes? What about their effects on HbA1c levels? To answer these questions, we conducted a review of the literature using the standard Prescrire methodology. Sulphonylureas have been in use for many years...
May 2015: Prescrire International
https://www.readbyqxmd.com/read/26000560/once-weekly-exenatide-as-a-treatment-for-type-2-diabetes
#20
REVIEW
Marisa B Schauerhamer, Holly Gurgle, Carrie McAdam-Marx
Type 2 diabetes mellitus is a progressive disease that requires pharmacologic treatment to prevent microvascular and macrovascular complications. As the disease progresses, most patients require combination therapy to achieve glucose control targets. Exenatide once weekly (EQW) is a glucagon-like peptide-1 receptor agonist approved in the United States in 2012 for use as a second-line agent to treat Type 2 diabetes mellitus. EQW has shown reductions in HbA1c and weight without causing an increased risk of hypoglycemia...
June 2015: Expert Review of Cardiovascular Therapy
keyword
keyword
110086
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"